Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 7/19/2025

Anticoagulation Therapy for Non-Valvular Atrial Fibrillation

Introduction to Anticoagulation Options

  • The American College of Chest Physicians recommends NOACs (Novel Oral Anticoagulants) over Vitamin K Antagonists (VKAs) like warfarin for eligible patients due to their superior safety profile and similar efficacy 1
  • NOACs demonstrate significant reductions in stroke, reduced intracranial hemorrhage, lower mortality, and similar major bleeding rates as warfarin, although with increased gastrointestinal bleeding with some agents 2

Efficacy and Safety of Apixaban

  • Apixaban shows a 31% reduction in major bleeding compared to warfarin, and an 11% reduction in all-cause mortality compared to warfarin 3
  • Apixaban has a better safety profile than rivaroxaban with similar efficacy in real-world studies, and no increased risk of gastrointestinal bleeding unlike rivaroxaban and dabigatran 1

Efficacy and Safety of Rivaroxaban

  • Rivaroxaban was non-inferior to warfarin for stroke prevention, but showed no significant reduction in ischemic stroke compared to warfarin, and similar major bleeding rates to warfarin 2
  • Rivaroxaban has an increased risk of gastrointestinal bleeding compared to warfarin 2

Warfarin Therapy

  • Warfarin requires regular INR monitoring with a target of 2.0-3.0, and is less effective when the time in therapeutic range (TTR) is <65% 1
  • Warfarin has a higher risk of intracranial hemorrhage compared to NOACs, and should be considered for patients with mechanical heart valves or severe renal impairment [2] [5]

Dosing and Administration

  • Apixaban can be used at a reduced dose in severe renal impairment, while rivaroxaban should be reduced to 15 mg daily if CrCl is 15-50 mL/min 5
  • Warfarin should be considered for severe renal impairment (CrCl <15 mL/min) 5

Bleeding Risk Assessment and Management

  • For patients at high risk of bleeding (HAS-BLED score ≥3), apixaban is preferred due to its lowest major bleeding risk, and modifiable bleeding risk factors should be addressed regardless of anticoagulant choice 1
  • Regular monitoring for adherence, side effects, and changing clinical parameters is essential regardless of anticoagulant choice 1

Inappropriate Therapies

  • Antiplatelet therapy alone (aspirin or clopidogrel) is not recommended for stroke prevention in AF, and suboptimal warfarin management (TTR <65%) should prompt consideration of switching to a NOAC 1
  • Incorrect DOAC dosing and neglecting bleeding risk assessment can lead to under- or over-anticoagulation and increased bleeding risk [5] [1]